Free Trial
→ Top Trader Reveals Stunning Black Friday Deal (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$0.95
-3.2%		$1.22
$0.95
▼
$7.54
$5.30M-2.08958,688 shs123,352 shs
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$3.51
-3.0%		$5.02
$1.90
▼
$10.54
$5.13M3.21426,321 shs4,721 shs
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$1.23
-7.8%		$2.31
$1.20
▼
$2.91
$5.42M-0.13165,678 shs44,714 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$0.38
+25.0%		$0.31
$0.00
▼
$0.85
$1.94M3.631,085 shs110 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-4.37%+4.16%-17.92%-29.39%-80.22%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-3.88%-9.73%-29.02%-34.42%-45.07%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-1.48%-11.33%-46.15%-47.84%-42.42%
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00%+717.44%+328.57%-14.29%-62.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
$0.95
-3.2%		$1.22
$0.95
▼
$7.54
$5.30M-2.08958,688 shs123,352 shs
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$3.51
-3.0%		$5.02
$1.90
▼
$10.54
$5.13M3.21426,321 shs4,721 shs
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$1.23
-7.8%		$2.31
$1.20
▼
$2.91
$5.42M-0.13165,678 shs44,714 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$0.38
+25.0%		$0.31
$0.00
▼
$0.85
$1.94M3.631,085 shs110 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover
The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-4.37%+4.16%-17.92%-29.39%-80.22%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-3.88%-9.73%-29.02%-34.42%-45.07%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-1.48%-11.33%-46.15%-47.84%-42.42%
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00%+717.44%+328.57%-14.29%-62.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
2.00
HoldN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
1.00
SellN/AN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
1.00
SellN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ORGS, KPRX, ACXP, and CNSP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/15/2026
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/15/2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
10/12/2026
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/29/2026
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/A$2.07 per shareN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A$7.29 per shareN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$16.02M0.34N/AN/A$4.38 per share0.28
Orgenesis Inc. stock logo
ORGS
Orgenesis
$662K2.93N/AN/A($7.26) per share-0.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$7.97M-$2.69N/AN/AN/AN/A-124.73%-87.48%N/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$15.85M-$23.59N/AN/AN/AN/A-204.25%-141.87%11/18/2026 (Estimated)
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$10.84M-$2.51N/AN/AN/AN/A-63.38%-44.33%N/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$48.17M-$11.51N/AN/AN/AN/AN/AN/AN/A

Latest ORGS, KPRX, ACXP, and CNSP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/18/2026Q3 2026
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$0.27N/AN/AN/AN/AN/A
11/12/2026Q3 2026
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.3767-$0.49-$0.1133-$0.49N/AN/A
11/12/2026Q3 2026
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$0.38-$0.28+$0.10-$0.28N/A$1.00 million
8/13/2026Q2 2026
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
-$0.3767-$0.53-$0.1533-$0.53N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/AN/AN/AN/AN/A
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
N/A
3.88
3.88
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A
5.86
5.86
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/A
8.97
8.97
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
11.53%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
14.02%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
76.97%
Orgenesis Inc. stock logo
ORGS
Orgenesis
22.56%

Insider Ownership

CompanyInsider Ownership
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
6.50%
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
1.82%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
0.52%
Orgenesis Inc. stock logo
ORGS
Orgenesis
1.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acurx Pharmaceuticals, Inc. stock logo
ACXP
Acurx Pharmaceuticals
45.56 million5.20 millionNo Data
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
81.46 million1.43 millionNot Optionable
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
134.42 million4.40 millionNot Optionable
Orgenesis Inc. stock logo
ORGS
Orgenesis
1505.17 millionN/ANo Data

Recent News About These Companies

Orgenesis (ORGS) Set to Post Quarterly Earnings on Wednesday
November 10 at 2:57 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31189137
Orgenesis (OTCMKTS:ORGS) Stock Price Breaks Below Two Hundred Day Moving Average - What's Next?
November 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31184259
MarketBeat estimates November 11 results for Orgenesis stock
October 16, 2026  |  ad-hoc-news.deA
Orgenesis stock fell 36.36 percent on October 6
October 7, 2026  |  ad-hoc-news.deA
Orgenesis stock gains 5.45 percent on October 2
October 4, 2026  |  ad-hoc-news.deA
Orgenesis Shareholders Approve Major Charter and Stock Increase
June 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ORGS/pressreleases/2292841/orgenesis-shareholders-approve-major-charter-and-stock-increase/
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio
March 26, 2026  |  newsfilecorp.comN
Okogen Acquires Ranpirnase Assets and Intellectual Property Portfolio
March 26, 2026  |  newsfilecorp.comN
Orgenesis Issues Alpha Warrant in New Financing Deal
January 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/orgenesis-issues-alpha-warrant-in-new-financing-deal?utm_source=marketbeat.com&utm_medium=referral
Orgenesis Subsidiary Secures Convertible Loan Agreement
September 16, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/orgenesis-subsidiary-secures-convertible-loan-agreement?utm_source=marketbeat.com&utm_medium=referral
Orgenesis Director Ashish Nanda Resigns
August 25, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/orgenesis-director-ashish-nanda-resigns?utm_source=marketbeat.com&utm_medium=referral
Orgenesis Faces Multiple Leadership Resignations in August
August 20, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/orgenesis-faces-multiple-leadership-resignations-in-august/ar-AA1KPxwD
Orgenesis Delays Filing of Quarterly Report
May 16, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/orgenesis-delays-filing-of-quarterly-report?utm_source=marketbeat.com&utm_medium=referral
Orgenesis Delays 10-K Filing Amid Financial Challenges
April 1, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/orgenesis-delays-10-k-filing-amid-financial-challenges?utm_source=marketbeat.com&utm_medium=referral
Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies
March 6, 2025  |  accessnewswire.comA
Orgenesis Inc. (ORGS) Stock Price, News, Quote & History - Yahoo Finance
February 9, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/ORGS/insider-sentiment/?err_load=1
Orgenesis secures $5M equity investment from Williamsburg Venture
January 29, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/orgenesis-secures-5m-equity-investment-from-williamsburg-venture-1034278292
Orgenesis Inc: Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings
January 28, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-01/64400832-orgenesis-inc-orgenesis-secures-up-to-dollar-5-million-equity-investment-from-williamsburg-venture-holdings-200.htm
Orgenesis Secures Up to $5 Million Equity Investment from Williamsburg Venture Holdings
January 28, 2025  |  accessnewswire.comA
Orgenesis Inc. Reports Q3 2024 Financial Results
November 15, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/orgenesis-inc-reports-q3-2024-financial-results-1034022417

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acurx Pharmaceuticals stock logo

Acurx Pharmaceuticals NASDAQ:ACXP

$0.95 -0.03 (-3.25%)
As of 01:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

CNS Pharmaceuticals stock logo

CNS Pharmaceuticals NASDAQ:CNSP

$3.51 -0.11 (-3.04%)
As of 12:55 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Kiora Pharmaceuticals stock logo

Kiora Pharmaceuticals NASDAQ:KPRX

$1.23 -0.10 (-7.29%)
As of 01:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Orgenesis stock logo

Orgenesis OTCMKTS:ORGS

$0.38 +0.08 (+25.00%)
As of 10:07 AM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas